CALC CBO Eric Roberts added 3,508 shares at $2.79

CALC #CALC — CalciMedica Inc | Healthcare |Biotechnology | USA |NASD | August 25, 2025.

Insider Purchase and Company Overview

Recent insider activity at CalciMedica Inc. (NASDAQ: CALC), a clinical-stage biotechnology company focused on developing novel therapies for acute and chronic inflammatory diseases, indicates growing executive confidence.

On August 21, 2025, Eric W. Roberts, the Chief Business Officer, purchased 3,508 shares at an average price of $2.79 per share, for a total value of $9,797. This transaction, disclosed via SEC Form 4 on August 25, 2025, at 09:30 AM EDT, increased his total holdings to 60,907 shares. This buy is part of a broader pattern of insider accumulation, as CalciMedica's Chief Medical Officer, Sudarshan Hebbar, also acquired shares in mid-August 2025 (9,563 shares on August 19 at ~$2.82 and 4,392 shares on August 15 at ~$2.79), signaling potential optimism amid the stock's recent volatility.

• stocktitan.net/sec-filings/CALC/form-4-calci-medica-inc-insider-trading-activity-01969e55b9c1.html
• investing.com/news/insider-trading-news/hebbar-calcimedica-cmo-buys-16k-in-calc-stock-93CH-4198177

The company reported Q2 2025 earnings on August 12, 2025, with a net loss of $6.0 million ($0.40 per share), in line with analyst estimates, and a cash position of $18.0 million as of June 30, 2025—sufficient to fund operations into mid-2026.

Key catalysts include ongoing Phase 2 trials (e.g., KOURAGE for acute kidney injury, with data expected in 2025), which could drive upside if positive.

• ir.calcimedica.com/news-releases/news-release-details/calcimedica-reports-second-quarter-2025-financial-results-and
• prnewswire.com/news-releases/calcimedica-reports-second-quarter-2025-financial-results-and-provides-clinical--corporate-updates-302526849.html
• stocktitan.net/news/CALC/calci-medica-reports-second-quarter-2025-financial-results-and-olp7rrfog9j7.html

Analysis Based on Insider Data

The cluster of insider buys in August 2025, including Roberts' purchase at $2.79, aligns with the chart's bottoming signals and post-earnings stability. Insiders often buy during perceived undervaluation, especially in biotech where clinical data can catalyze rapid moves.

With cash runway to mid-2026 and upcoming trial readouts, this activity implies executives see asymmetric upside potential, potentially discounting positive Phase 2 results. The buys occurred near support levels, reinforcing the $2.50-$2.80 zone as a accumulation area.

Charts:

• (1D)

• (1D)

• (3D)


SEC From 4:
sec.gov/Archives/edgar/data/1534133/000141588925022850/xslF345X05/form4-08252025_090801.xml

Forecast:

Replicating Roberts' buy at ~$2.79, the setup offers moderate-to-high reward potential in a biotech rebound play, assuming positive catalysts materialize. Based on the insider confidence, technical bottoming, and upcoming data, I project a 40-80% upside potential over 3-6 months if the reversal holds.

Entry Price: $2.79 (current/insider level).

Recommended Exit Targets:

— Conservative Target 1: $3.50 (25% profit, +$0.71/share) – Near-term resistance; exit on first signs of weakness or post-trial news.
— Moderate Target 2: $4.00 (43% profit, +$1.21/share)
— Aggressive Target 3: $5.00 (79% profit, +$2.21/share) – full exit if RSI hits overbought (>70) or on positive trial data release.

Overall Potential: 40-80% growth.

This forecast is speculative and not financial advice; always conduct due diligence.